company background image
MNTC

Mentice OM:MNTC Stock Report

Last Price

kr60.00

Market Cap

kr1.5b

7D

2.0%

1Y

-57.3%

Updated

16 Aug, 2022

Data

Company Financials +
MNTC fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

MNTC Stock Overview

Mentice AB (publ) provides endovascular simulation solutions to teaching entities, healthcare systems, and medical device manufacturers.

Mentice Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mentice
Historical stock prices
Current Share Pricekr60.00
52 Week Highkr185.00
52 Week Lowkr50.60
Beta1.36
1 Month Change-14.04%
3 Month Change-21.67%
1 Year Change-57.29%
3 Year Change-16.03%
5 Year Changen/a
Change since IPO-11.24%

Recent News & Updates

Jun 15
Mentice AB (publ) (STO:MNTC) Shares Could Be 44% Below Their Intrinsic Value Estimate

Mentice AB (publ) (STO:MNTC) Shares Could Be 44% Below Their Intrinsic Value Estimate

In this article we are going to estimate the intrinsic value of Mentice AB (publ) ( STO:MNTC ) by projecting its future...

Shareholder Returns

MNTCSE Healthcare ServicesSE Market
7D2.0%-1.6%0.9%
1Y-57.3%3.9%-20.9%

Return vs Industry: MNTC underperformed the Swedish Healthcare Services industry which returned 3.9% over the past year.

Return vs Market: MNTC underperformed the Swedish Market which returned -20.9% over the past year.

Price Volatility

Is MNTC's price volatile compared to industry and market?
MNTC volatility
MNTC Average Weekly Movement6.7%
Healthcare Services Industry Average Movement7.7%
Market Average Movement7.2%
10% most volatile stocks in SE Market12.6%
10% least volatile stocks in SE Market4.5%

Stable Share Price: MNTC is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: MNTC's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998117Göran Malmberghttps://www.mentice.com

Mentice AB (publ) provides endovascular simulation solutions to teaching entities, healthcare systems, and medical device manufacturers. The company operates through Medical Device Industry, Healthcare Systems, and Strategic Alliances segments. It provides software modules in the areas of acute ischemic stroke intervention, atrial septal defect and patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee intervention, carotid intervention, patient-specific simulation, coronary advanced and essentials, coronary intermediate, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic artery embolization, radiation safety, renal denervation, renal intervention, thoracic endovascular aortic repair, transarterial chemoembolization, transseptal puncture, uterine artery embolization, peripheral angiography, and vascular trauma and cardiac rhythm management, as well as supports interventionalists to transition from transfemoral to transradial access.

Mentice Fundamentals Summary

How do Mentice's earnings and revenue compare to its market cap?
MNTC fundamental statistics
Market Capkr1.53b
Earnings (TTM)-kr36.49m
Revenue (TTM)kr204.55m

7.5x

P/S Ratio

-42.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MNTC income statement (TTM)
Revenuekr204.55m
Cost of Revenuekr37.16m
Gross Profitkr167.39m
Other Expenseskr203.88m
Earnings-kr36.49m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Oct 26, 2022

Earnings per share (EPS)-1.43
Gross Margin81.83%
Net Profit Margin-17.84%
Debt/Equity Ratio0%

How did MNTC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MNTC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MNTC?

Other financial metrics that can be useful for relative valuation.

MNTC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.4x
Enterprise Value/EBITDA-63.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MNTC's PS Ratio compare to its peers?

MNTC PS Ratio vs Peers
The above table shows the PS ratio for MNTC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average10.3x
SYNT SyntheticMR
28x25.0%kr1.6b
RAY B RaySearch Laboratories
3.4x13.6%kr2.4b
PTRK Physitrack
7x23.2%kr653.7m
ORTI B Ortivus
2.8xn/akr272.2m
MNTC Mentice
7.5x21.6%kr1.5b

Price-To-Sales vs Peers: MNTC is good value based on its Price-To-Sales Ratio (7.5x) compared to the peer average (10.3x).


Price to Earnings Ratio vs Industry

How does MNTC's PE Ratio compare vs other companies in the European Healthcare Services Industry?

Price-To-Sales vs Industry: MNTC is expensive based on its Price-To-Sales Ratio (7.5x) compared to the Swedish Healthcare Services industry average (5.5x)


Price to Sales Ratio vs Fair Ratio

What is MNTC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MNTC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.5x
Fair PS Ratio9.3x

Price-To-Sales vs Fair Ratio: MNTC is good value based on its Price-To-Sales Ratio (7.5x) compared to the estimated Fair Price-To-Sales Ratio (9.3x).


Share Price vs Fair Value

What is the Fair Price of MNTC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MNTC (SEK60) is trading below our estimate of fair value (SEK120.93)

Significantly Below Fair Value: MNTC is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is Mentice forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


111.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MNTC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).

Earnings vs Market: MNTC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MNTC is expected to become profitable in the next 3 years.

Revenue vs Market: MNTC's revenue (21.6% per year) is forecast to grow faster than the Swedish market (10.9% per year).

High Growth Revenue: MNTC's revenue (21.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MNTC's Return on Equity is forecast to be low in 3 years time (19%).


Discover growth companies

Past Performance

How has Mentice performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-64.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MNTC is currently unprofitable.

Growing Profit Margin: MNTC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MNTC is unprofitable, and losses have increased over the past 5 years at a rate of 64% per year.

Accelerating Growth: Unable to compare MNTC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MNTC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-3.9%).


Return on Equity

High ROE: MNTC has a negative Return on Equity (-21.42%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Mentice's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MNTC's short term assets (SEK149.7M) exceed its short term liabilities (SEK138.5M).

Long Term Liabilities: MNTC's short term assets (SEK149.7M) exceed its long term liabilities (SEK10.2M).


Debt to Equity History and Analysis

Debt Level: MNTC is debt free.

Reducing Debt: MNTC has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MNTC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MNTC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Mentice current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MNTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MNTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MNTC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MNTC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: MNTC is not paying a notable dividend for the Swedish market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MNTC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Göran Malmberg (63 yo)

14.42yrs

Tenure

Mr. Goran Malmberg serves as Group Chief Executive Officer and President at Mentice AB. Mr. Malmberg had been the Chief Executive Officer and President of Mentice AB since March 2008. Mr. Malmberg has exte...


Leadership Team

Experienced Management: MNTC's management team is considered experienced (3.6 years average tenure).


Board Members

Experienced Board: MNTC's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.2%.


Top Shareholders

Company Information

Mentice AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: Mentice AB (publ)
  • Ticker: MNTC
  • Exchange: OM
  • Founded: 1998
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Implied Market Cap: kr1.534b
  • Shares outstanding: 25.57m
  • Website: https://www.mentice.com

Number of Employees


Location

  • Mentice AB (publ)
  • Odinsgatan 10
  • Gothenburg
  • Västra Götaland County
  • 411 03
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/16 00:00
End of Day Share Price2022/08/16 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.